Inotiv, Inc. (NASDAQ: NOTV)

Inotiv, Inc. is a contract research organization that provides nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries while also supplying research quality animals and diets to those sectors as well as to academia and government clients.

The company focuses on moving new drugs and medical devices through discovery and preclinical phases and in some cases through clinical development aiming to increase efficiency improve data quality and lower costs.

Inotiv generates revenue primarily from fees for its discovery and safety assessment services and from the sale of research models diets bedding enrichment products and related services.

The company operates through the following segments: Discovery and Safety Assessment and Research Models and Services.

• Discovery and Safety Assessment: This segment provides discovery and translational sciences and safety assessment services including nonclinical development and in certain cases clinical development to support researchers working on small molecule drug candidates biotherapeutics and biomedical devices using both GLP and non GLP conditions.

• Research Models and Services: This segment offers purpose bred animal research models including small and large species diet bedding and enrichment products under the Teklad brand and a suite of research model services such as surgical modifications breeding colony management health monitoring transgenic model creation quarantine cryopreservation and antibody development.

In the Discovery and Safety Assessment segment Inotiv competes with two public companies in the United States and three public companies in China while in the Research Models and Services segment it faces seven main competitors consisting of one public US company four privately held US firms one government funded non‑profit US entity and one privately held European company.

The company’s competitive advantages include its integrated service model deep scientific expertise in histology pathology physiology surgery analytical chemistry drug metabolism pharmacokinetics and toxicology and its commitment to high standards of animal welfare and regulatory compliance.

Inotiv serves a diverse client base that includes emerging biopharmaceutical firms large multinational pharmaceutical companies contract research organizations academic institutions and government agencies with sales to over 2,200 companies during the twelve months ended September 30 2025.